• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Poll: What Will Be the Strongest Trend in 2021?

Article

Which of these selections do you think is the most powerful trend in medicine to emerge from the pandemic?

Which trend in medicine do you expect to gain most momentum in 2021?

Governments act proactively in the development of medicines.
Pandemic mortality spurs health system reform.
Patients research their own health needs and options via digitized information.
Greater efforts are made to build trust in vaccines.

Related Content
question mark | Image credit: Duminda - stock.adobe.com

Quiz: Biosimilar Market Dynamics and Trends

April 2nd 2024
Article

Have you been keeping up with the latest market trends? Take this quiz to find out how well you know the global biosimilars market.

question mark | Image credit: Duminda - stock.adobe.com

Quiz: The Global Biosimilar Landscape

March 1st 2024
Article

Explore the dynamic world of global biosimilar markets and policies! What do you know about the international biosimilar industry?

question mark | Image credit: Duminda - stock.adobe.com

Quiz: How Well Do You Know These Biosimilar Policy Essentials?

February 9th 2024
Article

Test your knowledge of major biosimilar policies, including challenging regulatory frameworks from around the world.

question mark | Image credit: Duminda - stock.adobe.com

Quiz: The Basics of Biosimilars

January 8th 2024
Article

Intro to Biosimilars is now in session! Test yourself on how well you know these biosimilar basics.

In Canada, the Northwest Territories Switch to Biosimilars

In Canada, More Mandatory Switching

December 23rd 2021
Article

In Canada, a new jurisdiction inaugurates mandatory switching to biosimilars.

Alvotech Gains EC Approval for Adalimumab Biosimilar

Alvotech Gains EC Approval for Adalimumab Biosimilar

December 16th 2021
Article

Alvotech has received European Commission (EC) approval to begin marketing its adalimumab biosimliar AVT02, the company announced this week.

© 2024 MJH Life Sciences

All rights reserved.